MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial
On December 18, 2024, MetaVia announced positive topline results from the Phase 2a clinical trial of DA-1241 in patients with presumed metabolic...
510 Views
MTVA: NeuroBo Becomes MetaVia Topline Results for Phase 2a
n November 18, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced a strategic realignment with a name change to MetaVia Inc. (MTVA).
398 Views
NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024
On November 7, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced financial results for the third quarter of 2024 and provided a business...
181 Views
NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024
On November 7, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced financial results for the third quarter of 2024 and provided a business...
249 Views
NRBO: Positive SAD Part 1 Data MAD Part 2 Results Expected in 1Q25
On September 30, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced positive topline results from the single ascending dose (SAD) Part 1 portion...
347 Views